tbuckley/cabot-search huggingface dataset:
Acoustic analysis of respiratory sounds in infants with wheezing
Authors: Irina Melnikova, Vasilina Grigoreva, Yuri Mizernitski
Journal: European Respiratory Journal (2012)

The aim of the study was to determine functional acoustic characteristics of breath by bronchophonographic method (BPG) in infants with wheezing.  Methods: We observed 24 children (2 month-3 years) with wheezing. The patients were divided into two groups (Gr), the Gr1 (n=14) - atopic children and Gr2 (n=10) - non-atopic children. The control group (C) included 27 healthy non-atopic children (2 month - 3 years of age). Computerized BPG by computer diagnostic complex «Pattern» (MEI, Russia) (0,2-12,6 kHz) before and after inhalation of salbutamol (BTS) was provided all patients after the disappearance of wheezing. It were used coefficients of the general acoustic breath work (ABW) – φ1 (0,2-1,2 kHz), φ2 (1,2-5,0 kHz), φ3 (5,0-12,6 kHz), representing relation of level ABW in a given frequency range of the level general ABW.  Results. There were significantly more high parameters of general ABW, φ2, φ3 in the patients of Gr1 and Gr2 in comparison with Gr3 (p  Conclusion: These preliminary results showed that the infants after the disappearance of wheezing still demonstrate the significant functional acoustic disorders. It was more expressed at atopic children then non-atopic. It can be important in relation of early debut of bronchial asthma.
Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers.
Authors: M Nishio, T Koshikawa, T Kuroishi, M Suyama, K Uchida, Y Takagi, O Washimi, T Sugiura, Y Ariyoshi, T Takahashi, R Ueda, T Takahashi
Journal: Journal of Clinical Oncology (1996)

This study was conducted to evaluate the prognostic significance of p53 abnormalities in primary, resected non-small-cell lung cancer (NSCLC).Methodologic validation of immunohistologic detection of p53 abnormalities in routine pathology sections was assessed using 31 lung cancer specimens for which p53 gene status was known from our previous molecular biologic studies. Applying the optimized cutoff value, we evaluated the prognostic significance of p53 abnormalities in an independent cohort of 208 NSCLC patients with complete follow-up data, whose resections were consecutively performed between January 1984 and December 1988.Immunohistologic detection of p53 abnormalities appeared to be reliable and showed approximately 90% concordance with the p53 gene status. Using the selected cutoff value of 10%, 46% of 208 NSCLCs showed p53 abnormalities. There was no relationship between p53 abnormalities and clinical outcome in the entire cohort, which represented all histologic subtypes of NSCLC (P = .58). Based on the reasoning that the influence of p53 abnormalities may have been obscured by distinct biologic roles depending on histologic subtypes, we also separately analyzed subsets of patients with adenocarcinomas (n = 100) and with squamous cell carcinomas (n = 88) and found that it may be a useful prognosticator only in adenocarcinoma patients (P = .04).p53 abnormalities are not a significant prognostic factor in primary, resected NSCLC when all histologic subtypes are combined, but may be a useful prognosticator for adenocarcinomas. Additional studies are warranted for further evaluation, specifically of adenocarcinomas.
Blocking neutrophil diapedesis prevents hemorrhage during thrombocytopenia
Authors: Carina Hillgruber, Birgit Pöppelmann, Carsten Weishaupt, Annika Kathrin Steingräber, Florian Wessel, Wolfgang E. Berdel, J. Engelbert Gessner, Benoît Ho-Tin-Noé, Dietmar Vestweber, Tobias Goerge
Journal: The Journal of Experimental Medicine (2015)

Spontaneous organ hemorrhage is the major complication in thrombocytopenia with a potential fatal outcome. However, the exact mechanisms regulating vascular integrity are still unknown. Here, we demonstrate that neutrophils recruited to inflammatory sites are the cellular culprits inducing thrombocytopenic tissue hemorrhage. Exposure of thrombocytopenic mice to UVB light provokes cutaneous petechial bleeding. This phenomenon is also observed in immune-thrombocytopenic patients when tested for UVB tolerance. Mechanistically, we show, analyzing several inflammatory models, that it is neutrophil diapedesis through the endothelial barrier that is responsible for the bleeding defect. First, bleeding is triggered by neutrophil-mediated mechanisms, which act downstream of capturing, adhesion, and crawling on the blood vessel wall and require Gαi signaling in neutrophils. Second, mutating Y731 in the cytoplasmic tail of VE-cadherin, known to selectively affect leukocyte diapedesis, but not the induction of vascular permeability, attenuates bleeding. Third, and in line with this, simply destabilizing endothelial junctions by histamine did not trigger bleeding. We conclude that specifically targeting neutrophil diapedesis through the endothelial barrier may represent a new therapeutic avenue to prevent fatal bleeding in immune-thrombocytopenic patients.
Incidence and predictive factors of depression in patients with metastatic breast cancer: A prospective study
Authors: R. Conforti, F. Andre, F. Zenasni, G. Gomez Abuin, S. Delaloge, M. Di Palma, M. Spielmann
Journal: Journal of Clinical Oncology (2005)

8165 Background: Although some reports suggest that the incidence of depression in patients with metastatic breast cancer is high, only a few studies specifically focus on the predictive factors for depression. The identification of predictive factors for depression in cancer patients could help to screen it. In the present study, we have evaluated the incidence and predictive factors for depression in patients with metastatic breast cancer. Methods: A Beck depression inventory short form was given to 178 patients with metastatic breast cancer followed at the Institut Gustave Roussy between december 2003 and april 2004. We looked at the correlation between age, mastectomy, ongoing chemotherapy, site of metastases, marital status, belief in god and the beck score. Patients who presented a Beck score above 4 were considered as depressed. Results: 132 patients replied to the questionnaire (74%). Of these patients, 65% received chemotherapy at the time of evaluation and 31% presented a liver metastasis. A Beck score >4 was observed in 33 patients (25% of questionnaires). Age, locoregional treatment, ongoing chemotherapy and site of metastases did not predict the Beck score. The only predictive factors for depression were the marital status (p=0.04) and the lack of god belief (p=0.04). Although a psycho-oncology service was available in the hospital, only 5 patients (15%) who presented a beck score >4 were followed by a specialist in psycho-oncology. Conclusion: This study confirms that depression is a frequent and underdiagnosed situation in patients with metastatic breast cancer, and suggests that social and cultural factors are more important that clinical characteristics to predict depression. No significant financial relationships to disclose.
Analysis of tuberculosis treatment outcomes in the European Union and European Economic Area: efforts needed towards optimal case management and control
Authors: D Manissero, V Hollo, E Huitric, C Ködmön, A Amato-Gauci
Journal: Eurosurveillance (2010)

An analysis of surveillance data was performed to assess treatment outcomes of patients belonging to selected calendar year cohorts. Twenty-two countries in the European Union (EU) and European Economic Area (EEA) reported treatment outcome monitoring data for culture-confirmed pulmonary tuberculosis (TB) cases reported in 2007. The overall treatment success rate was 73.8% for all culture-confirmed pulmonary cases and 79.5% for new culture-confirmed pulmonary cases. For the cohort of new culture-confirmed TB cases, only three countries achieved the target of 85% success rate. This underachievement appears to be a result of relative high defaulting and unknown outcome information. Case fatality remains high particularly among cases of national origin. This factor appears attributable to advanced age of the national cohort. Treatment outcomes for multidrug-resistant tuberculosis were reported by 15 countries, with a range of 19.8% to 100% treatment success at 24 months. The data underline the urgent need for strengthening treatment outcome monitoring in the EU and EEA in order to ensure an effective programme implementation and case management that will ultimately contribute to TB elimination.
Eastern Cooperative Oncology Group Phase I Trial of Protracted Venous Infusion Fluorouracil Plus Weekly Gemcitabine With Concurrent Radiation Therapy in Patients With Locally Advanced Pancreas Cancer: A Regimen With Unexpected Early Toxicity
Authors: Mark S. Talamonti, Paul J. Catalano, David J. Vaughn, Richard Whittington, R. Daniel Beauchamp, Jordan Berlin, Al B. Benson
Journal: Journal of Clinical Oncology (2000)

PURPOSE: We performed a phase I trial of protracted venous infusion (PVI) fluorouracil (5-FU) plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer to determine the maximum-tolerated dose of gemcitabine that could be safely administered. We also sought to identify the toxicities associated with this treatment protocol. PATIENTS AND METHODS: Seven patients with locally advanced pancreas cancer were treated with planned doses of radiation (59.4 Gy) and PVI of 5-FU (200 mg/m 2 /d) with gemcitabine doses of 50 to 100 mg/m 2 /wk. RESULTS: Two of three patients at the 100-mg/m 2 /wk dose level experienced dose-limiting toxicity (DLT), as did three of four at the 50-mg/m 2 /wk dose level. One patient experienced a mucocutaneous reaction described as a Stevens-Johnson syndrome that was attributed to chemotherapy. Three patients developed gastric or duodenal ulcers with severe bleeding requiring transfusion. One patient developed severe thrombocytopenia lasting longer than 4 weeks. Three of the five episodes of DLT developed at radiation doses ≤ 36 Gy. CONCLUSION: Based on this experience, we cannot recommend further investigation of regimens incorporating gemcitabine into regimens of radiation with PVI 5-FU. The mechanism of this synergistic toxicity remains to be determined.
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database
Authors: Manish A. Shah, Lindsay A. Renfro, Carmen J. Allegra, Thierry André, Aimery de Gramont, Hans-Joachim Schmoll, Daniel G. Haller, Steven R. Alberts, Greg Yothers, Daniel J. Sargent
Journal: Journal of Clinical Oncology (2016)

Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown. A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. For each end point, continuous-time risk was modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependent treatment comparisons. Addition of oxaliplatin significantly reduced the risk of recurrence within the first 14 months post treatment for patients with stage II disease and within the first 4 years for patients with stage III disease. Oxaliplatin also significantly reduced risk of death from 2 to 6 years post treatment for patients with stage III disease, with no differences in timing of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death compared with FU + LV alone). Patients with stage II disease receiving oxaliplatin did not exhibit a significant reduction in risk of death in the first 6 years post treatment. Recurrence risk peaked near 14 months for both treatments, and risk of recurrence and death increased with increased tumor and nodal burden. These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy.
Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer
Authors: S. Rodenhuis, L.T. Vlasveld, R. Dubbelman, R. Roodbergen, J.H. Schornagel, J. Wanders, S.P. Israels, E. Bais, W.W. Ten Bokkel Huinink, D.J. Richel
Journal: Annals of Oncology (1992)
Raphael James Kerry
Authors: Raphael James Kerry, Robert M Kerry
Journal: BMJ (2016)

Raphael James Kerry (“Ray”) wrote: “I was born in Nottingham and educated at High Pavement School. The summer of 1939 was highly significant, with a scholarship to read science at University College, Nottingham, as the war started. I became a founder member of Nottingham University Air Squadron, going to a flying school in Florida in peacetime America.

“As the war ended I switched to medicine at the …
α1-Antitrypsin genotype unaffected by age
Authors: M. Dahl, B. G. Nordestgaard, N. Seersholm
Journal: Thorax (2005)

In a recent otherwise excellent editorial in Thorax ,1 Dr Seersholm indicated that our previous results on the decline in forced expiratory volume in 1 second (FEV1) based on the Copenhagen City Heart Study2 are biased. We disagree, and rather believe that our study of the general population is prone to less bias than case-control or family based studies.

Dr Seersholm argues that, because we genotyped study participants after measurement of FEV1 in 1976–8, 1981–4, and 1991–4, our results are biased.1 Certainly, if conventional risk factors are measured after development of disease, the disease might be the cause of the risk …
Treatment of women with abdominal carcinomatosis of suspected ovarian origin and prognostic importance of response to primary chemotherapy
Authors: C. J. Gallagher, G. Orphanos, M. Perianan, A. Saha, P. Wilson, R. Reznek, D. Oram, A. Jeyarajah, K. Reynolds, J. Shepherd
Journal: Journal of Clinical Oncology (2005)

5069 Background: women with advanced abdominal carcinomatosis of suspected ovarian origin (ACSO) are a common problem for the gynecological cancer team. We reviewed the response and overall survival (OS) of a prospectively agreed protocol of epithelial ovarian cancer (EOC) type primary chemotherapy and surgery for these patients. Methods: 64 patients(pts) age 28–83 median 67 yrs with ACSO unsuitable for primary debulking surgery were treated 1998–2004 concurrently with 212 women with EOC. Diagnosis was by cytology in 32 and biopsy in 32 pts,and all pts had full imaging and endoscopic staging as necessary. Non-adenocarcinoma histology and non-gynecological primaries were excluded. Chemotherapy(CT) 6 cycles carboplatin AUC5 q21d (26pts), carboplatin AUC5 plus paclitaxel 175 mg/m2 q21d (34pts), other platinum combinations (4pts), surgery when possible comprised TAH BSO omentectomy, lymphadenectomy and debulking to <2cm. Results: 3pts received only 1 CT cycle and progressed off study, 61pts completed at least 2 cycles and were assessed for surgery, 9 early responders had interval debulking (IDS) after 3 cycles and then completed their CT, 14 had delayed primary surgery(DPS) after 6 cycles of CT. 41pts did not have surgery because of failure to respond (21pts), poor PS or advanced age (20pts). Objective response at completion of treatment was 9CR, 27 PR (ORR 56.2% 95% CI 44.0–68.4%), 12 SD, 9 NE, median OS 13.3 mo. CA125 response was assessable in 53pts of whom 16(30%) normalized. In univariate and multivariate analysis CT response was the most significant factor for optimal surgery and for survival. Median OS varied from that of responders with optimal surgery of 40.8 mo, to 10.5 mo for pts not able to be debulked (p <0.01), and for responders not fit for surgery med.OS was 17.7 mo vs 7.2 mo for non responders (p <0.05). Conclusions: Response by imaging or CA125 to a trial of platinum based CT identified a group of women with ACSO suitable for IDS/DPS with a med.OS of 29.2 mo very simillar to concurrently treated stage 3/4 EOC. In contrast those not responding within 3 cycles had a med.OS of 7.2 mo. and need an alternative treatment strategy No significant financial relationships to disclose.
Adjuvant therapy in postmenopausal node-positive breast cancer.
Authors: A Goldhirsch, R D Gelber, F Cavalli, C M Rudenstam, M N Tattersall
Journal: Journal of Clinical Oncology (1985)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1985.3.7.1045 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 4020404 Adjuvant therapy in postmenopausal node-positive breast cancer. A GoldhirschxA GoldhirschSearch for articles by this author , R D GelberxR D GelberSearch for articles by this author , F CavallixF CavalliSearch for articles by this author , C M RudenstamxC M RudenstamSearch for articles by this author , M N TattersallxM N TattersallSearch for articles by this author https://doi.org/10.1200/JCO.1985.3.7.1045 PDF "Adjuvant therapy in postmenopausal node-positive breast cancer.." Journal of Clinical Oncology, 3(7), pp. 1045–1047© 1985 by American Society of Clinical Oncology
A Gln747→Pro Substitution in the IIb Subunit Is Responsible for a Moderate IIbβ3Deficiency in Glanzmann Thrombasthenia
Authors: Seiji Tadokoro, Yoshiaki Tomiyama, Shigenori Honda, Morio Arai, Naomasa Yamamoto, Masamichi Shiraga, Satoru Kosugi, Yuzuru Kanakura, Yoshiyuki Kurata, Yuji Matsuzawa
Journal: Blood (1998)
Modification of the Epidermal Growth Factor Response by Ammonia in Renal Cell Hypertrophy
Authors: HAROLD A. FRANCH
Journal: Journal of the American Society of Nephrology (2000)

Abstract. Epidermal growth factor (EGF) causes proliferation in renal tubular cells but, when it is combined with transforming growth factor-β1, it causes hypertrophy by a mechanism that requires the activity of the retinoblastoma family of proteins. In contrast, ammonia causes hypertrophy by decreasing lysosomal proteolysis; in some cell types, it also decreases cellular proliferation. These studies were designed to determine whether ammonia, like transforming growth factor-β1, could convert EGF-induced hyperplasia to hypertrophy. Cultured NRK-52E cells were incubated with EGF and/or ammonia and the protein/DNA ratio was measured, as a marker of hypertrophy. Addition of ammonia to EGF-treated NRK-52E cells converted EGF-induced hyperplasia to hypertrophy, because of a decrease in DNA synthesis. The mechanism involved no change in EGF-induced protein synthesis. Inhibition of lysosomal function with a proton pump inhibitor or lysosomal protease inhibitors also converted the response of EGF-treated cells to hypertrophy. Expression of the human papilloma virus 16 E7 protein (which inactivates all members of the retinoblastoma family) prevented ammonia from converting EGF-induced hyperplasia to hypertrophy. It is concluded that ammonia converts EGF-induced hyperplasia to hypertrophy by a mechanism that involves suppression of lysosomal function and this response can be blocked by inhibiting the activity of the retinoblastoma family of proteins.
Frequent mutation of the 5' noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas.
Authors: Gianluca Gaidano, Antonino Carbone, Cristina Pastore, Daniela Capello, Anna Migliazza, Annunziata Gloghini, Silvio Roncella, Manlio Ferrarini, Giuseppe Saglio, Riccardo Dalla-Favera
Journal: Blood (1997)
Chemoradiation and maintenance chemotherapy with cisplatin and 5-fluorouracil in anal squamous cell carcinoma
Authors: J. Ahn, B. Cho, H. Choi, H. Jeung, S. Rha, J. Roh, G. Kim, B. Kim, H. Chung
Journal: Journal of Clinical Oncology (2006)

14057 Background: Chemoradiation is the standard treatment for anal carcinoma. Mitomycin-C (MMC) with 5-fluorouracil (5-FU) is the widely used regimen, but MMC is not a radiation sensitizer and has significant toxicities. This study was conducted to update our experience in treating anal carcinomas with an external beam radiation and continuous infusion of 5-FU with cisplatin. Methods: Twenty-eight patients with locally advanced squamous cell carcinoma of the anus were treated between 1995 and 2005. The primary tumor and involved lymph nodes received a total of 41.4–64.8 Gy and 39.6–60.4 Gy, respectively. Chemotherapy consisted of 5-FU (1,000 mg/m 2 CI, D1–5 and D36–40) and cisplatin (80 mg/m 2 IVF, D2 and D37) q 4weeks for 4 courses. Results: One patients had T1 lesions, 15 had T2, 7 had T3, and 5 patients had T4 disease. Seventeen patients presented with clinically detectable lymphadenopathy. Eight patients failed to start maintenance chemotherapy due to events during chemoradiation. Of the 19 patients who started maintenance chemotherapy, 3 failed to complete all four courses due to intolerance to chemotherapy. With a median follow-up duration of 68.5 months, the actuarial 5-year OS rate was 83.2 %, the DFS rate 80.7%, and the colostomy-free survival was 91.7%. Patterns of recurrence were local relapses in 3 patients, distant metastases in 2, and both in 1, respectively. Seventeen patients (60.7%) developed moist skin reaction, which frequently caused the interruption of radiotherapy. Principal grade 3/4 hematologic toxicities were neutropenia in 10 patients (35.8%) and thrombocytopenia in 4 (14.2%). The most common late complications were lymphedema (14.3%). Conclusions: Our results demonstrate that combined modality therapy with external beam radiation, cisplatin and 5-FU yields an excellent outcome in terms of survival and sphincter preservation which is comparable to the results of MMC regimens. No significant financial relationships to disclose.